Connor Clark & Lunn Investment Management Ltd. Sells 68,325 Shares of Adverum Biotechnologies Inc (ADVM)

Share on StockTwits

Connor Clark & Lunn Investment Management Ltd. cut its holdings in Adverum Biotechnologies Inc (NASDAQ:ADVM) by 43.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,325 shares of the biotechnology company’s stock after selling 68,325 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.14% of Adverum Biotechnologies worth $278,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Adverum Biotechnologies in the fourth quarter valued at approximately $66,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Adverum Biotechnologies in the third quarter valued at approximately $155,000. Wells Fargo & Company MN grew its holdings in shares of Adverum Biotechnologies by 169.5% in the third quarter. Wells Fargo & Company MN now owns 34,142 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 21,474 shares in the last quarter. MetLife Investment Advisors LLC grew its holdings in shares of Adverum Biotechnologies by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 43,973 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 15,632 shares in the last quarter. Finally, Exane Asset Management grew its holdings in shares of Adverum Biotechnologies by 36.0% in the third quarter. Exane Asset Management now owns 68,000 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 18,000 shares in the last quarter. 59.51% of the stock is owned by institutional investors.

ADVM has been the subject of several recent analyst reports. BidaskClub raised Adverum Biotechnologies from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th. Zacks Investment Research lowered Adverum Biotechnologies from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Adverum Biotechnologies currently has an average rating of “Hold” and an average price target of $6.55.

ADVM stock opened at $6.02 on Friday. Adverum Biotechnologies Inc has a 12-month low of $2.62 and a 12-month high of $7.72.

Adverum Biotechnologies (NASDAQ:ADVM) last released its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.39 million. Adverum Biotechnologies had a negative return on equity of 30.18% and a negative net margin of 4,505.40%. On average, sell-side analysts anticipate that Adverum Biotechnologies Inc will post -1.15 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/4239778/connor-clark-lunn-investment-management-ltd-sells-68325-shares-of-adverum-biotechnologies-inc-advm.html.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage.

Recommended Story: Trading signals using Bollinger bands

Want to see what other hedge funds are holding ADVM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adverum Biotechnologies Inc (NASDAQ:ADVM).

Institutional Ownership by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Selfkey  24-Hour Trading Volume Hits $967,433.00
Selfkey 24-Hour Trading Volume Hits $967,433.00
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd  This Quarter
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd This Quarter
Waves Community Token Trading 1.3% Higher  Over Last Week
Waves Community Token Trading 1.3% Higher Over Last Week
Telcoin Price Tops $0.0006 on Major Exchanges
Telcoin Price Tops $0.0006 on Major Exchanges
Crystal Clear  Market Capitalization Tops $26,650.00
Crystal Clear Market Capitalization Tops $26,650.00
SwissBorg  Market Cap Tops $5.04 Million
SwissBorg Market Cap Tops $5.04 Million


© 2006-2019 Ticker Report